Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01903967 : Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH)
PhaseN/A
AgesMin: 18 Years Max: 85 Years
Eligibility
Inclusion Criteria:

- Only patient with complete clinical, radiological and hormonal data available during
yearly follow-up will be included.

- Preoperative MRI will be used to classify the tumour as invasive, and postoperative
MRI will be collected to confirm recurrence or progression of the tumour.

- Presence of tumour fragments fixed in Holland-Bouin's fluid or Neutral Buffered
Formalin fixative available for aCGH analysis.

Exclusion Criteria:

- Patient who underwent systematic post-operative radiotherapy.

- Patient presenting Multiple Endocrine Neoplasia type 1 (MEN1) or aryl hydrocarbon
receptor interacting protein (AIP) mutation since mechanism of tumorigenesis are
different to sporadic pituitary tumours.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01903967      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740